Biosimilars Month in Review: June 2024

The biosimilars month in review underscores the efficacy and safety of biosimilars in rheumatology, including recent studies supporting the growing confidence in these treatments across disease spaces. Findings show biosimilars are viable options that maintain or improve patient outcomes while offering potential cost savings. Additionally, regulatory discussions focused on streamlining approval processes to enhance patient access and affordability further stressed the ongoing impact of biosimilars in rheumatological care.